Ignite Creation Date:
2025-12-24 @ 4:39 PM
Ignite Modification Date:
2026-01-25 @ 2:55 AM
Study NCT ID:
NCT04198766
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-18
First Post:
2019-12-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Sponsor:
Inhibrx Biosciences, Inc
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-12-10
Start Date Type:
ACTUAL
Primary Completion Date:
2026-10-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-05-12
Completion Date Type:
ESTIMATED
First Submit Date:
2019-12-11
First Submit QC Date:
None
Study First Post Date:
2019-12-13
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-17
Last Update Post Date:
2025-12-18
Last Update Post Date Type:
ESTIMATED